OUR LEAD PROGRAM

A clinically advanced program for CMT1A. A new path to evaluate what comes next.
LUT001 (formerly PXT3003) is an investigational oral combination with an extensive clinical development history, including Phase 2, Phase 3 studies and long-term follow-up
Phase 3 development history · Next-step evaluation
UNDERSTANDING CMT1A
A lifelong disease. A need for better options.
Charcot-Marie-Tooth disease type 1A is an inherited demyelinating peripheral neuropathy associated with duplication of the PMP22 gene and excess PMP22 expression. Damage to peripheral nerves can lead to progressive muscle weakness, sensory loss and difficulty walking or using the hands.
There is currently no approved disease-modifying drug for CMT1A. Care focuses on managing symptoms and supporting function.

THE COMBINATION RATIONALE
A combination designed around complementary mechanisms
LUT001 — investigational fixed-dose combination
LUT001 combines baclofen, naltrexone and D-sorbitol at fixed low doses. Preclinical research investigated effects on PMP22 expression, myelination, nerve function and protection. These experimental findings provide a rationale for clinical investigation in patients.
Baclofen
+
Naltrexone
+
D-sorbitol
CLINICAL EVIDENCE
The complete clinical picture
The development record includes encouraging findings and important setbacks. Both matter when deciding how PXT3003 should move forward.
ONLS stands for Overall Neuropathy Limitations Scale. It measures functional limitation; lower scores indicate less limitation.
These studies differ in design, populations and analysis. These summaries are not a pooled analysis or a direct comparison between trials.
Phase 2 and follow-up
Earlier exploratory Phase 2 research and subsequent open-label follow-up extend the development record. Open-label observations have limitations and cannot substitute for controlled evidence.
CHINA PROGRAM
A separate development program in China
Tasly/GeneNet leads development in China, separately from Lutetia’s activities. Tasly had submitted a marketing authorization application for PXT3003 to China’s National Medical Products Administration.
A submission is not an approval and does not establish authorization in another region.
THE LUTETIA DEVELOPMENT STRATEGY
Building on the evidence. Learning from the past. Advancing what comes next.
Lutetia is reviewing the total PXT3003 evidence base to define the next development strategy for LUT001 in the United States and Europe, with Japan under evaluation.
Clinical evidence
Assess efficacy, safety, study limitations and the questions further development must address.
CMC: Chemistry, Manufacturing and Controls.
The next objective is a development plan grounded in the full clinical record and the requirements for a reliable product. Further work depends on financing, operational readiness and regulatory feedback; additional studies may be needed.
CMC and manufacturing
Review formulation, stability, manufacturing and supply requirements.
Regulatory strategy
Evaluate development options and prepare for discussions with relevant authorities.
Information for patients and families
This corporate website does not offer treatment or determine eligibility for a clinical study. Please discuss care and research questions with your healthcare professional. A trial-register link does not imply current recruitment or treatment access.
Selected publications and study information
Clinical publications
Preclinical research
Sponsor disclosures and registry
